Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil

Vaccine

Volumn 31, Issue 37, 2013, Pages 4047-4053

  Ho, Yeh Li ^a   Brandão, Angela Pires ^b   de Cunto Brandileone, Maria Cristina ^b   Lopes, Marta Heloisa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Adults; Combination vaccines; HIV; Pneumococcal conjugate vaccines; Pneumococcal polysaccharide vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULTS; COMBINATION VACCINES; HIV; PNEUMOCOCCAL CONJUGATE VACCINES; PNEUMOCOCCAL POLYSACCHARIDE VACCINE;

ADULT; BRAZIL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; VACCINATION; YOUNG ADULT;

EID: 84881545848     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.065     Document Type: Article

References (46)

1. Chiang H.H.H.C., Lee C.M., Chen H.Y., Chen M.Y., Sheng W.H., Hsieh S.M., et al. Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors. Crit Care 2011, 14:R202.
2. Akgun K.M., Pisani M., Crothers K. The changing epidemiology of HIV-infected patients in the intensive care unit. J Intensive Care Med 2011, 26:151-164.
3. Kourtis A.P., Ellington S., Bansil P., Jamieson D.J., Posner S.F. Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine. J Acquir Immune Defic Syndr 2010, 55:128-131.
4. Cohen A.L., Harrison L.H., Farley M.M., Reingold A.L., Hadler J., Schaffner W., et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010, 24:2253-2262.
5. Jordano Q., Falcó V., Almirante B., Planes A.M., del Valle O., Ribera E., et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004, 38:1623-1628.
6. Mascart-Lemone F., Gerard M., Libin M., Crusiaux A., Franchioly P., Lambrechts A., et al. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J Infect Dis 1995, 172:1253-1260.
7. Falco V., Jordano Q., Cruz M.J., Len O., Ribera E., Campins M., et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 2006, 24:2567-2574.
8. Dworkin M.S., Ward J.W., Hanson D.L., Jones J.L., Kaplan J.E. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001, 32:794-800.
9. Center for Disease Control and Prevention Guidelines for prevention and treatment of opportunistic infections in adults and adolescents. MMWR 2009, 58:33.
10. Braido F., Bellotti M., De Maria A., Cazzola M., Canonica G.W. The role of pneumococcal vaccine. Pulm Pharmacol Ther 2008, 21:608-615.
11. Breiman R.F., Keller D.W., Phelan M.A., Sniadack D.H., Stephens D.S., Rimland D., et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000, 160:2633-2638.
12. Hung C.C., Chen M.Y., Hsieh S.M., Hsiao C.F., Sheng W.H., Chang S.C. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004, 22:2006-2012.
13. Lopez-Palomo C., Martin-Zamorano M., Benitez E., Fernandez-Gutierrez C., Guerrero F., Rodriguez-Iglesias M., et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004, 72:517-524.
14. Penaranda M., Falco V., Payeras A., Jordano Q., Curran A., Pareja A., et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 2007, 45:e82-e87.
15. Teshale E.H., Hanson D., Flannery B., Phares C., Wolfe M., Schuchat A., et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 2008, 26(46):5830-5834.
16. Rodriguez-Barradas M. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the veterans aging cohort 5-site study. Clin Infect Dis 2008, 46:1093-1100.
17. Pedersen R.H., Lohse N., Ostergaard L., Sogaard O.S. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011, 12:323-333.
18. French N., Moore M., Haikala R., Kayhty H., Gilks C.F. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis 2004, 190:707-712.
19. Pitsiou G.G., Kioumis I.P. Pneumococcal vaccination in adults: does it really work. Respir Med 2011, 105:1776-1783.
20. Musher D.M., Sampath R., Rodriguez-Barradas M.C. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence. Clin Infect Dis 2011, 52:633-640.
21. de Roux A., Schmole-Thoma B., Siber G.R., Hackell J.G., Kuhnke A., Ahlers N., et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008, 46:1015-1023.
22. Jackson L.A., Neuzil K.M., Nahm M.H., Whitney C.G., Yu O., Nelson J.C., et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007, 25:4029-4037.
23. Goldblatt D., Southern J., Andrews N., Ashton L., Burbidge P., Woodgate S., et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009, 49:1318-1325.
24. Lazarus R., Clutterbuck E., Yu L.M., Bowman J., Bateman E.A., Diggle L., et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011, 52:736-742.
25. Ahmed F., Steinhoff M.C., Rodriguez-Barradas M.C., Hamilton R.G., Musher D.M., Nelson K.E. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996, 173:83-90.
26. Feikin D.R., Elie C.M., Goetz M.B., Lennox J.L., Carlone G.M., Romero-Steiner S., et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001, 20:545-553.
27. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362:812-822.
28. Kroon F.P., van Dissel J.T., Ravensbergen E., Nibbering P.H., van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000, 19:886-894.
29. Lesprit P., Pedrono G., Molina J.M., Goujard C., Girard P.M., Sarrazin N., et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007 Nov 30, 21(18):2425-2434.
30. PAHO/WHO Informe Regional de SIREVA II, datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores 2008, 37-46. OPS, Washington, DC.
31. Nicoletti C., Brandileone M.C., Guerra M.L., Levin A.S. Prevalence, serotypes, and risk factors for pneumococcal carriage among HIV-infected adults. Diagn Microbiol Infect Dis 2007, 57:259-265.
32. World Health Organization Training Manual for Enzyme-Linked Immunosorbent Assay for the Quantitation of Streptococcus pneumoniae Serotype Specific IgG (Pn PS ELISA) (WHO13) 2004, World Health Organization, Geneva, Switzerland, (accessed 02.09.08). http://www.vaccine.uab.edu/.
33. Plikaytis B., Holder P., Carlone G. Program ELISA for Windows, Version 2.15 2005, Centers for Disease Control and Prevention, Atlanta, GA, USA.
34. Quataert S.A., Kirch C.S., Wiedl L.J., Phipps D.C., Strohmeyer S., Cimino C.O., et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995, 2:590-597.
35. Concepcion N., Frasch C.E. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol 1998, 5:199-204.
36. Center for Disease Control and Prevention Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2012, 61:816-819.
37. O'Brien K.L. Pneumococcal conjugate vaccine, polysaccharide vaccine, or both for adults? We're not there yet. Clin Infect Dis 2009, 49:1326-1328.
38. Subramaniam K.S., Segal R., Lyles R.H., Rodriguez-Barradas M.C., Pirofski L.A. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis 2003, 187:758-768.
39. Balmer P., Cant A.J., Borrow R. Anti-pneumococcal antibody titre measurement: what useful information does it yield?. J Clin Pathol 2007, 60:345-350.
40. Madhi S.A., Adrian P., Cotton M.F., McIntyre J.A., Jean-Philippe P., Meadows S., et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010, 202:355-361.
41. Nunes M.C., Madhi S.A. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012, 8:161-173.
42. Penaranda M., Payeras A., Cambra A., Mila J., Riera M. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010, 24:1226-1228.
43. Feikin D.R., Elie C.M., Goetz M.B., Lennox J.L., Carlone G.M., Romero-Steiner S., et al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diagn Lab Immunol 2004, 11:137-141.
44. Henckaerts I., Goldblatt D., Ashton L., Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006, 13:356-360.
45. Concepcion N.F., Frasch C.E. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8:266-272.
46. Esposito S., Droghetti R., Faelli N., Lastrico A., Tagliabue C., Cesati L., et al. Serum concentrations of pneumococcal anticapsular antibodies in children with pneumonia associated with Streptococcus pneumonia infection. Clin Infect Dis 2003, 37:1261-1264.